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HOX genes are vital for all aspects of mammalian growth and differentiation, and their dysregulated expression is related to
ovarian carcinogenesis. The aim of the current study was to establish the prognostic value of HOX dysregulation as well as its
role in platinum resistance. The potential to target HOX proteins through the HOX/PBX interaction was also explored in the con-
text of platinum resistance. HOX gene expression was determined in ovarian cancer cell lines and primary EOCs by QPCR, and
compared to expression in normal ovarian epithelium and fallopian tube tissue samples. Statistical analysis included one-way
ANOVA and t-tests, using statistical software R and GraphPad. The analysis identified 36 of the 39 HOX genes as being overex-
pressed in high grade serous EOC compared to normal tissue. We detected a molecular HOX gene-signature that predicted poor
outcome. Overexpression of HOXB4 and HOXB9 was identified in high grade serous cell lines after platinum resistance devel-
oped. Targeting the HOX/PBX dimer with the HXR9 peptide enhanced the cytotoxicity of cisplatin in platinum-resistant ovarian
cancer. In conclusion, this study has shown the HOX genes are highly dysregulated in ovarian cancer with high expression of
HOXA13, B6, C13, D1 and D13 being predictive of poor clinical outcome. Targeting the HOX/PBX dimer in platinum–resistant
cancer represents a potentially new therapeutic option that should be further developed and tested in clinical trials.
Ovarian cancer is the 5th leading cause of cancer death in
women in the western world and it is estimated there were
22,280 new cases and 15,500 deaths due to the disease in the
US in 2012.1 It is the most lethal of the gynaecological malig-
nancies largely due to late diagnosis. Standard treatment
involves debulking surgery followed by a combination of tax-
ane and platinum-based therapy. Initially most women
respond to platinum-based therapy, but the majority suffer
disease recurrence due to drug resistance. It is therefore
essential to introduce new therapeutic approaches to improve
treatment at diagnosis and/or provide an effective second line
treatment.
There are different types of ovarian cancer classified by
the cell type they originate from. The most common form,
accounting for >90% of ovarian cancers, is epithelial ovarian
cancer (EOC), and the high grade serous (HGS) subtype
accounts for 80% of EOC cases.
The epithelial ovarian tumours undergo M€ullerian differ-
entiation, which suggests that differentiation-regulatory fac-
tors may contribute to their progression. This mechanism
has been shown to involve homeobox (HOX) genes2,3 which
play important roles in tissue differentiation during embry-
onic development. The HOX genes constitute a family of
transcription factors, and in mammals 39 HOX genes have
been identified. They are organised into 4 paralogous clusters
(A, B, C and D) located on 4 different chromosomes. During
development of the female reproductive system four HOX
genes, HOXA9, HOXA10, HOXA11 and HOXA13 are
expressed uniformly along the M€ullerian duct axis. HOXA9
becomes expressed in the fallopian tubes, HOXA10 is
expressed in the developing uterus, HOXA11 in the lower
uterine segment and cervix and HOXA13 in the upper
vagina.4 It is thought that inappropriate expression of these
genes is an early step in epithelial ovarian neoplasia as they
induce aberrant epithelial differentiation. Studies which have
analysed HOX gene expression in ovarian cancer cell lines
and a small number of tumours have found dysregulated
expression of certain HOX genes compared to normal tissue.5
Numerous studies have also demonstrated dysregulated HOX
gene expression in other cancers such as lung, prostate,
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breast, colon and bladder cancer.6–9 The recent genomic
analysis of HGS ovarian cancer (HGS-OvCa) by the Cancer
Genome Atlas (TCGA) researchers found a number of
somatic copy number alterations with three members of the
HOXB family, HOXB2, B5 and B8 among the focally ampli-
fied regions. The group divided HGS ovarian cancer into
four expression subtypes “immunoreactive,” “differentiated,”
“proliferative” and “mesenchymal” on the basis of gene
expression, and high expression of HOX genes was a charac-
teristic of the mesenchymal subtype.10 High expression of
HOX genes makes them a potential target for therapeutic
intervention. One possible method is the use of a peptide
that disrupts the interaction between HOX proteins and co-
factor PBX. HXR9 is a small peptide designed to mimic the
hexapeptide sequence found in HOX proteins of paralogue
groups 1–9,11 therefore acting as a specific competitive inhib-
itor of the HOX/PBX interaction preventing the subsequent
binding of the HOX/PBX dimer to target DNA sequences.
This in effect inhibits the transcription of target genes. Previ-
ous studies have shown that HXR9 is capable of blocking
this interaction in vitro and in vivo11–13 and antagonising the
HOX/PBX interaction induces apoptosis.11–15
The role of aberrant HOX dysregulation in EOC is not yet
understood. The aim of the current study was to establish
the prognostic value of HOX dysregulation as well as its role
in developing platinum resistance. The potential to target
HOX function through the HOX/PBX interaction was also
explored in the context of platinum resistance.13
Material and Methods
Cell lines and reagents
The human ovarian adenocarcinoma-derived HGS cell line
SKOV-3, clear cell carcinoma derived cell line TOV-21G and
the endometrioid carcinoma derived cell line TOV-112D
were obtained from the American Type Culture Collection
(LGC Promochem, Teddington, UK). The SKOV-3 cell line
has since been reclassified as an endometrioid subtype due to
the lack of a p-53 mutation and the presence of the endome-
trioid associated ARID1A mutation.16 Therefore, the SKOV-3
cell line will be considered as an endometrioid cell line in
this paper. SKOV-3 cells were cultured in McCoys’s 5A
modified medium (Sigma, Poole, UK) supplemented with
10% (v/v) heat-inactivated foetal bovine serum (FBS) (Invi-
trogen, Paisley, UK). TOV-112D and TOV-21G cells were
cultured in 1:1 mixture of MCDB 105 medium (Sigma) sup-
plemented with 1.5 g/L sodium bicarbonate and Medium 199
(Invitrogen), with 15% heat-inactivated FBS (Invitrogen). The
epithelial HGS carcinoma cell line derived from peritoneal
ascites COV-318 and the paired HGS ovarian carcinoma cell
lines PEO1, PEO4, PEO14 and PEO23 were obtained from
the HPA Cell Culture Collection (HPA, Salisbury, UK).17
These cell lines were authenticated by either STR profiling
(DDC Medical, OH) or LCG Standards (Middlesex, UK).
COV-318 cells were cultured in DMEM medium (Sigma)
with 10% heat-inactivated FBS and 2 mM glutamine (Sigma).
PEO cell lines were maintained in RPMI1640 media with
10% heat-inactivated FBS. All media was supplemented with
1% penicillin (10,000 U/ml)/streptomycin (10 mg/ml)
(Sigma). Cell cultures were maintained at 378C in a humidi-
fied, 5% CO2 incubator. Cisplatin sensitivity of cell lines was
verified by MTS assay after 72 hr cisplatin treatment.
RNA isolation, cDNA production and quantitative
real time PCR (qRT-PCR)
Two total RNA samples from normal human ovarian tissue
were purchased from OriGene (Cambridge, UK). All cell
lines were grown in normal growth medium in 6-well plates
at a density range to ensure overnight growth resulted in
until 80% confluency before RNA extraction took place. RNA
was isolated from cell lines using the RNeasyV
R
Plus Mini Kit
(Qiagen Ltd, Crawley, UK) following the manufacturer’s
instructions. This included the use of gDNA eliminator col-
umns to remove genomic DNA contamination. Total RNA
extracted from 20–30 mg ovarian tumour or ovarian normal
tissue stored in RNAlaterVR (Sigma) was isolated using the
gentleMACS dissociator followed by RNA extraction using
the RNeasyV
R
Plus Mini Kit (Qiagen). RNA purity was veri-
fied by the 260 nm/280 nm absorbance ratio, measured using
the Nanodrop (Thermo Fisher, MA). Ratios of 1.9–2.0 were
considered “pure” RNA as described by manufacture. cDNA
was synthesised from RNA using the Cloned AMV First
Strand Synthesis Kit (Invitrogen) following the manufac-
turer’s protocol. qRT-PCR was performed using the Strata-
gene MX3005P Real Time PCR machine (Agilent
Technologies UK Ltd, Stockport, UK) and SYBRVR Green
JumpStartTM Taq ReadyMixTM (Sigma). Oligonucleotide pri-
mers were designed to facilitate the unique amplification of
b-actin and each HOX gene. Melt curves and gels were run
What’s new?
Homeobox (HOX) genes, which serve key functions in DNA repair and cell differentiation, are aberrantly expressed in ovarian
cancer. How they influence the disease, however, remains enigmatic. Here, a five-gene signature, involving elevated expres-
sion of HOXA13, B6, C13, D1 and D13, was found to predict poor clinical outcome in epithelial ovarian cancer. Meanwhile,
platinum resistance in high grade serous ovarian cancer cells was linked to HOXB4 and HOXB9 overexpression. In mice, treat-
ment with HXR9, a peptide that disrupts interactions between HOX and co-factor PBX, effectively recovered cisplatin sensitivity
in resistant tumors, opening the path to novel therapeutic options in ovarian cancer.
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originally to validate the primers and check for single bands
of the correct product size. Relative expression was calculated
using the Livak comparative Ct method.18
Synthesis of HXR9 and CXR9 peptides
HXR9 is an 18 amino acid peptide consisting of the previ-
ously identified hexapeptide sequence that can bind to PBX
and nine C-terminal arginine residues (R9) that facilitate cell
entry.11 The N-terminal and C-terminal amino bonds are in
the D-isomer conformation, which has previously been shown
to extend the half-life of the peptide to 12 h in human
serum.11 CXR9 is a control peptide that lacks a functional
hexapeptide sequence but still includes the R9 sequence. All
peptides were synthesized using conventional column based
chemistry and purified to at least 80% (Biosynthesis).
Analysis of cell death and apoptosis
Cells were plated in flat bottomed 96-well plates and incu-
bated for 24 hr until 70% confluent. Cells were treated with
HXR9 or CXR9 at a range of dilutions for 2 hr. Cell viability
was measured via the MTS assay (Promega, Southampton,
UK) according to the manufacturer’s instructions. To detect
morphological changes consistent with apoptosis, cells were
plated in 24-well plates and incubated overnight to reach
70% confluency. Cells were then treated for 2 hr with 2%
FBS media, the control peptide CXR9 or the active peptide
HXR9 at the IC50 (Concentration of drug needed to induce
50% cell death, as determined by the MTS assay) and double
the IC50. Cells were then harvested by incubating in trypsin-
EDTA (Sigma) at 378C until detached and dissociated. Apo-
ptotic cells were identified using a Beckman Coulter Epics XL
flow cytometer (argon laser, excitation wavelength 488 nm,
FL-2 and FL-4 detectors) and the Annexin V-PE apoptosis
detection kit (BD Pharmingen) as described by the manufac-
turer’s protocol. Caspase-3 activity was measured using the
EnzCheck Caspase-3 Assay Kit (Molecular Probes), using the
protocol defined by the manufacturer.
Calculating synergy
To measure synergistic interaction between HXR9 and cispla-
tin, cells were plated in a 96-well plate and treated with
either HXR9 or cisplatin alone or in combination at concen-
trations of the drugs IC50 and 62-, 4- and 8-fold this con-
centration. Cell viability was then measured by the MTS
assay (as described earlier) and the presence of synergy was
analysed based on the Chou-Talalay method using CalcuSyn
version 2.0 software (Biosoft, Stapleford, UK).19 The interac-
tion between HXR9 and cisplatin was quantified by deter-
mining the combination index (CI). Using this method,
CI< 1 indicates synergism, CI5 1 indicates an additive effect
antagonism (CI> 1) between drugs.
Clinical data
A cohort of 99 patients with corresponding age, stage, time
to progression (TTP), overall survival (OS), histology and
chemotherapy information was used in the analysis of pri-
mary ovarian tumours (Supporting Information Table 1).
Fresh biopsy tissue specimens were obtained during surgery
from human subjects with ovarian cancer or other gynaeco-
logical conditions from the Royal Surrey County Hospital,
Guildford following informed consent and ethical approval.
Samples were immediately stored in RNAlaterVR and stored at
2208C for later use. Each biopsy was confirmed by a pathol-
ogist to be either cancerous of ovarian origin or normal ovar-
ian tissue. OS and TTP were measured from the date of
diagnosis. The duration of OS was measured up to the date
of death or, for patients still alive the 1st October 2012, when
statistical analysis was performed. The duration of TTP was
the minimum amount of time until clinical progression, or
death. Only cases where causes of death were due to disease
were used to calculate OS. HOX gene expression was
obtained by qRT-PCR and values were normalised to house-
keeping gene b-actin. All sample and data collection received
an ethical approval by the institutional ethics committee
(MREC-09/H1103/50).
Mouse in vivo study
All experiments were conducted in accordance with the United
Kingdom Co-ordinating Committee on Cancer Research
(UKCCCR) guidelines for the Welfare of Animals in Experi-
mental Neoplasia20 and were approved by the University of
Surrey Ethics Committee. The mice were kept in positive pres-
sure isolators in 12 hr light/dark cycles and food and water
were available ad libitum. Six-8 week old female balb/C NUDE
mice (Charles River, Kent, UK) were inoculated subcutane-
ously with a suspension 100 mL Hanks media (Sigma) contain-
ing 106 SKOV-3 cells in 50% matrigel (BD Bioscience). Once
tumours reached a volume of approximately 100 mm3, mice
were randomised into 4 treatment groups, each containing 10
mice: PBS alone, Cisplatin alone, HXR9 alone, Cisplatin and
HXR9 in combination. Mice in the HXR9 group received an
initial dose of 100 mg/kg HXR9 intratumorally (IT), with
subsequent dosing of 10 mg/kg twice weekly. The cisplatin
treatment group received a weekly dose of 3 mg/kg via intra-
peritoneal injection (IP). PBS was used as a control. Drug con-
centrations were used based on previous experiments.13 The
mice were monitored carefully for signs of distress, including
behavioural changes and weight loss.
Statistical analysis
All data analysis and manipulation of primary ovarian
tumours were performed using R (an integrated set of soft-
ware tools for data manipulation, calculation and graphical
display).
Four test statistics were used to evaluate the change of
gene expression. For variables with two groups (i.e., Age, OS
and chemotherapy) the t test was used for parametric analy-
sis and the Mann-Whitney test was used as a non-parametric
analysis. For variables with three or more groups (i.e., TTP
and Stage) the one-way ANOVA was used for parametric
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analysis and the Kruskal-Wallis was used as a non-
parametric analysis. Differential expression and interactions
based on ANOVA. The Benjamini and Hochberg and the
Bonferroni correction was applied to cell line data and ovar-
ian tumour data, respectively, to account for multiple testing.
Principle component analysis (PCA) was performed and the
first two principle components are plotted. The heatmaps
include row Z-score transformation (genes), and are plotted
in red–blue colour scale with red indicating high expression
and blue indicating low expression. Analysis of OS was calcu-
lated using the Kaplan–Meier method using GraphPad
PRISM Version 5.0 (GraphPad Software). Hazard ratio (HR)
and confidence intervals (CI) were calculated using the Log
rank model.
Results
HOX gene expression in ovarian cancer cell lines
and normal ovarian and fallopian tube tissue
To evaluate the changes in HOX gene expression in EOC we
compared the relative expression of all 39 HOX genes in nor-
mal ovarian and fallopian tube tissue to a number of ovarian
cancer cell lines.
The HOX expression profile was analysed in a panel of 5
HGS ovarian cancer cell lines, 2 endometrioid cell lines and
1 clear cell carcinoma cell line and compared with 10 normal
ovarian and 3 fallopian tube tissue samples. A highly dysre-
gulated pattern of HOX gene expression was found in the
EOC cell lines whereas normal tissue showed very little or no
HOX gene expression (Fig. 1).
The HGS cell lines showed marked dysregulation but this
varied significantly across the panel. The COV-318 (HGS)
cell line showed two HOX genes, with HOXA9, being signifi-
cantly upregulated, whilst the PEO14 (HGS) cell line had 23
HOX genes that were significantly upregulated when com-
pared to normal tissue.
HOX expression in platinum sensitive and resistant
ovarian cancer cell lines
To evaluate differences in HOX expression between platinum
sensitive and resistant EOC, 2 paired HGS cancer cell lines
derived from patients with platinum sensitive and resistant
Figure 1. HOX expression in ovarian cancer cell lines of high grade serous (HGS), endometrioid and clear cell carcinoma subtypes and nor-
mal ovarian and fallopian tube tissue. Heat map showing differential HOX expression between 5 HGS, 2 endometrioid and 1 clear cell ovar-
ian carcinoma cell lines and 10 normal ovarian and 3 fallopian tube tissue samples. Expression of each gene was determined by
quantitative PCR (qRT-PCR) from at least three independent experiments and expression is relative to the house keeping gene b-actin.
Figure 2. HOX gene expression of paired platinum sensitive and platinum resistant ovarian cancer cell lines. The comparison of HOX gene
expression profiles between patient derived cell lines before (PEO1 and PEO14) and after (PEO4 and PEO23) developing platinum resist-
ance. Heat map shows differential HOX expression between platinum sensitivity statuses of cell lines.
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disease were analysed. Each pair was acquired from separate
patients at the time when the tumour was deemed clinically
sensitive to platinum and at a later time-point after develop-
ing platinum resistance. PEO1 and PEO14 - platinum sensi-
tive cell lines, were compared with PEO4 and PEO23,
platinum resistant cell lines, respectively.21 We found signifi-
cant differences in the HOX expression profile in platinum
resistant and platinum sensitive cell lines. The PEO4 (plati-
num resistant cell line) showed a significant increase of
HOXB3 and HOXB4 gene expression compared to its paired
sensitive cell line, PEO1. PEO23 (platinum-resistant) also has
a relatively higher expression of HOXB4 when compared to
its platinum-sensitive couterpart-PEO14, and in addition, ele-
vated expression of HOXB9. Cell line gene expression data
was pooled according to platinum sensitivity status and the
resistant cell lines showed an overall higher HOX expression
compared to normal and sensitive cell lines (Fig. 2).
HOX expression in primary EOC
To comprehensively evaluate HOX gene expression profiles
in clinically relevant HGS EOC we analysed tumours from a
cohort of 73 HGS ovarian cancer patients and compared it to
10 normal ovarian and 3 fallopian tube tissue samples
(patients’ characteristics are summarized in Table 1). HGS
ovarian tumours exhibited a significant upregulation in the
expression of 36 of the 39 HOX genes when compared to
their expression in normal tissue samples (Fig. 3). The
strongly overexpressed genes included HOXA9 (p5 1.86 3
1028), previously reported to be related to the HGS histo-
type,3 however, HOXA3 was expressed to a far higher level,
(p5 9.55 3 10210).
There were significant differences in HOX expression pro-
files between the HGS and endometrioid histological subtypes
with up-regulation of HOXA7, A9, A10, A13, B1, B4, B5, B13,
C9, C13, D9 and D10 in the endometrioid samples. HOXB2
Figure 3. HOX gene expression in high grade serous ovarian tumours. (a) Heat map showing differentially expressed HOX genes between
high grade serous (HGS) ovarian tumours and normal ovarian and fallopian tube tissue. HOX gene expression data for HGS tumours (yel-
low) were compared to 10 normal ovarian tissues (green) and 3 fallopian tube sample (purple) to find upregulation of 36 genes in the HGS
tumours. HOX expression profiles were determined by quantitative PCR (qRT-PCR) and normalised to housekeeping gene b-actin. Each col-
umn represents a gene and each row represents a sample. Column-wise z scores transformation (genes) was used. Red colour for a gene
indicates expression above the median and blue indicates expression below the median.
Table 1. Kaplan–Meier analysis of the 5-HOX gene prognostic signature showing the median overall survival for patients who do not express
the gene as compared to patients whose tumours show expression of the genes listed below
Gene
Median overall
survival (months) No. of patients p values Hazard ratio 95% Confidence interval
HOXC13 36 37 0.0128 8.264 1.396–12.75
HOXB6 36 36 0.0145 8.286 1.365–14.67
HOXA13 44 39 0.0317 4.508 1.145–12.17
HOXD13 36 37 0.0308 6.834 1.153–12.79
HOXD1 36 37 0.025 4.692 1.206–11.61
Hazard ratios and Confidence intervals were calculated using the Log rank model.
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was the only gene to show a significant difference between
HGS and clear cell carcinomas, although this might reflect
the small sample size.
A 5-HOX gene signature predicts poor OS
The HOX expression profile in HGS EOC was subsequently
correlated with clinical characteristics such as age, stage, TTP
and OS. The HOX expression profile in EOC also correlated
with OS. We found that 5 HOX genes: HOXA13, B6, C13, D1
and D13 were expressed significantly more strongly in the
tumours of patients with poor survival with higher expression
of these genes found in all deceased patients. Each of these
genes were individually analysed by the Kaplan–Meier
method and the result from the analysis are summarised in
Table 1.
Targeting the HOX/PBX dimer in platinum-resistant EOC
The aberrant HOX expression found in EOC makes them a
potential therapeutic target. As the function of HOX genes is
partly based on the binding of HOX proteins to the PBX and
MEIS co-factors, targeting these co-factors could impair the
oncogenic potential of HOX. PBX and MEIS proteins are
present in both the nucleus and cytoplasm in ovarian carci-
nomas, however only MEIS is expressed in normal ovarian
epithelia.22 These co-factors are important for ovarian carci-
nogenesis, most likely through potentiating the function of
HOX proteins. A peptide called HXR9 has been designed to
target the interaction between HOX proteins (members of
paralogue groups 1–9) and PBX.11 This drug has been shown
previously to induce apoptosis in cancer cells with highly
dysregulated HOX expression profiles,11,12,14,15 including the
ovarian cancer cell line SKOV-3.13 SKOV-3 is platinum-
resistant, although its origin has recently been questioned.16
In view of the gross HOX dysregulation pattern seen in
platinum-resistant tumours we have used HXR9 alone and in
combination with cisplatin to evaluate its efficacy in this set-
ting. HXR9 and its control peptide –CXR9 (which has an
identical polyarginine cell penetrating sequence to HXR9 but
has a single alanine substitution in its hexapeptide sequence
that renders inactive) have been described previously.11 All
cell lines treated with HXR9 demonstrated an increase in
cFOS expression, which is thought to be at least partly
responsible for HXR9-induced cell death (data not shown).11
When analysed with flow cytometry for Annexin-V-PE there
was a significant increase in the number of cells in late apo-
ptosis after HXR9 treatment compared to untreated cells
(Figs. 4a and 4b). Previous publications have also demon-
strated the apoptosis inducing capacity of HXR9 in ovarian
cancer cell lines showing PARP cleavage and caspase-3 activ-
ity in treated cancer cells.11 The in vitro experiments showed
that HGS cell lines were all sensitive to HXR9 treatment but
not to CXR9 and when combined with cisplatin there was
synergy between HXR9 and cisplatin as shown in Supple-
mentary Table 2. There was also enhanced cell killing in vivo
using a combination of HXR9 and cisplatin over each drug
used alone when treating mice bearing SKOV-3 tumours
(Fig. 5). Despite a good synergy effect seen in vitro, the effect
in vivo was not as powerful and the combination of HXR9
and cisplatin was only marginally more active than HXR9
alone. This however may be cell line dependent. Combined
HXR9 and cisplatin provided a survival advantage, with a
hazard ratio of 1.98 (95% CI, 20.88–6.58; p5 0.098) deter-
mined by the Log-rank model.
Discussion
This study confirms that HOX genes are highly dysregulated
in ovarian cancer and that targeting the HOX/PBX interac-
tion in platinum resistant tumours is of therapeutic value.
Little to no HOX expression was found in normal ovarian
tissue, whereas increased expression of certain groups of
HOX genes was found in the majority of ovarian cancers.
The HGS carcinoma subtype shows the highest degree of
heterogeneity in HOX expression for both cell lines and pri-
mary tumours, whereas endometrioid subtypes show a very
distinct HOX expression profile. The HGS histological sub-
type is known to have a very heterogeneous nature, exhibit-
ing a wide range of underlying genetic alterations, which may
explain this variation. However, the functional redundancy
between HOX genes may mean the net effect of HOX overex-
pression is similar even in cells expressing different sets of
HOX genes.23
Previous studies have shown that the over-expression of
specific HOX genes determines the histological subtype, with
HOXA9 being overexpressed in HGS subtypes, HOXA10 in
endometrioid and HOXA11 in mucinous.3 In this study, we
found that HOXA9 is overexpressed in only 3 of the 8 HGS
cell lines, but is also expressed in the clear cell and endome-
trioid cell lines. With regards to the primary tumours,
HOXA9 is significantly overexpressed in the HGS samples;
however HOXA10 and HOXA11 are also expressed at high
levels in HGS tumours, which has not been previously
reported. The endometrioid cell lines show an overall higher
level of HOX expression than the HGS cell lines, including
HOXA9 and HOXA10.
HOXA7 has been previously reported to play a role in the
differentiation of ovarian surface epithelia (OSE) into EOC.24
We found that HOXA7 is overexpressed in the HGS cancers
as well as in the endometrioid carcinomas compared to nor-
mal ovarian tissue. In addition, HOXA13 is overexpressed in
the endometrioid tumours. This suggests that the HOXA
genes play a role in the determination of histological sub-
types, but the differences in expression are not as clear as
previously suggested by Cheng et al. The high expression of
HOXA10 in the endometrioid cell lines and primary tumours
does support a role for this gene in the differentiation of
endometrioid tumours; however the high level of heterogene-
ity in cancer calls for caution in the interpretation of the
results as the level of gene expression may differ in individual
tumour samples.
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Figure 4. HXR9 induces apoptosis in ovarian cancer cell lines. Ovarian cancer cell were assessed for apoptosis or necrosis through
annexin/propidium iodine staining after HXR9 treatment. (a) The bargraphs show the percentage of cells in early apoptosis, late apoptosis,
and necrosis, as well as viable cells, when untreated, treated at the HXR9 IC50 dose or double the IC50 dose for each cell line or equivalent
CXR9 dose. Error bars show the SEM. p-values <0.05 are denoted as *, <0.005 as ** and<0.001 as *** with respect to untreated cells.
(b) Example flow cytometry plots for untreated; CXR9 25 mM; CXR9 50 mM; HXR9 25 mM and HXR9 50 mM treated SKOV-3 cells.
T
um
or
M
ar
ke
rs
an
d
Si
gn
at
ur
es
1614 Ovarian cancer
Int. J. Cancer: 139, 1608–1617 (2016) VC 2016 The Authors International Journal of Cancer published by John Wiley & Sons Ltd on behalf of
UICC
Figure 4. (Continued). [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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Although the function of the HOX genes in cancer remains
unclear, there have been reports that they act as tumour sup-
pressor genes or oncogenes. In ovarian cancer both HOXB7
and B13 expression has been linked to the invasive characteris-
tics of ovarian cancer cells,25 and HOXB7 has been shown to be
a regulator of bFGF- a potent mitogenic and angiogenic fac-
tor26 and involved in double strand break repair,27 whereas
HOXB13 promotes cell proliferation.28
We found that 9 out of the 10 HOXB genes were upregu-
lated, the most significant being HOXB4, B5, B7 and B13.
HOXB4 upregulation has been shown to be associated with the
development of platinum resistance in cell lines, and its over-
expression in ovarian cancer has been reported previously in a
relatively small study using only 4 cell lines and 7 ovarian can-
cer tumour samples,29 but no oncogenic function for this gene
has been proven. HOXB4 has been implicated as a cancer-
related gene in other malignancies, including breast cancer,
leukaemia and lung canceR.30–32 The recent genomic analysis
of HGS ovarian cancer by the Cancer Genome Atlas (TCGA)
researchers found a number of somatic copy number altera-
tions and three members of the HOXB family, HOXB2, B5 and
B8 were among the focally amplified regions33 further support-
ing a possible oncogenic role of HOXB genes in ovarian cancer
and emphasising the overlapping functions which exist
between HOX genes.34
Significant differences in HOX gene expression were found
between platinum sensitive and resistant cell lines. Platinum-
resistant cell lines show upregulation of HOX genes from the
HOXB cluster. Although there was a difference between the
three paired cell lines tested, HOXB4 and HOXB9 overexpres-
sion was common in two of the three cell lines (when com-
pared to the platinum-sensitive counterpart). These results
therefore demonstrate that HOXB genes are likely to play a
role in developing platinum resistance; although further study
is needed to understand the mechanism of this interaction.
Survival analysis revealed a cluster of 5 HOX genes,
HOXA13, B6, C13, D1 and D13, that was strongly associated
with a poor OS in HGS patients. HOXA13 is usually expressed
in the upper vagina4 playing a role in M€ullerian duct differen-
tiation during development, but has been reported to be over-
expressed in ovarian cancer cell lines.25 HOXA13 was linked to
poor OS in oesophageal squamous cell carcinoma patients, and
the same study found its expression in cell lines enhanced
tumour growth in vitro and in vivo.35 High-throughput micro-
array analysis of gastric cancer patients revealed HOXA10 and
A13 over-expression with HOXA13 upregulation significantly
associated with an aggressive phenotype, and a prognostic
marker for poor OS.36 Highly deregulated expression of the
HOXA cluster has also been found in hepatocellular carcinoma
(HCC), in particular HOXA13.37
Up-regulation of HOXB6 has also been reported in ovar-
ian cancer before, in addition to HOXB7.38 Data from this
study and previous reports of high HOXB expression in ovar-
ian cancer suggests that the HOXB gene products play a role
in ovarian tumourgenesis.
HOXC13 has a role in DNA replication,39 supporting an
oncogenic function. A role in human cancer has also been
reported with overexpression found in metastatic melanoma40
and fusion with NUP98 has been associated with acute mye-
loid leukaemia (AML).41 The HOXD1 gene appears to be
involved in cell differentiation,42 whereas HOXD13 is deregu-
lated in breast and cervical cancer and melanoma.43–45 A
large HOXD13 expression analysis by Cantile and colleagues
in 79 different tumour types also supports its role in neoplas-
tic transformation.46
Determination of HOX gene dysregulation may be under-
taken routinely in the clinical setting using fresh or archived
patient tissue and such information could be used for stratify-
ing patients in terms of prognosis. Furthermore, we have
shown that our novel agent HXR9, a peptide capable of dis-
rupting HOX gene function by inhibiting HOX binding to its
co-factor, PBX, has significant anti-tumour efficacy,11–15 which
is increased when used in combination with cisplatin. This syn-
ergy could be explained due to the role of HOX genes in DNA
repair pathways27 but further work investigating this is needed.
HOX gene dysregulation therefore represents a potential ovar-
ian cancer target with a low likelihood of cross resistance to
conventional chemotherapeutic agents. Both HXR9 and small
molecule inhibitors of the HOX/PBX dimer are currently being
evaluated as novel cancer agents in preclinical models.
Conclusion
This comprehensive analysis of HOX gene expression in
ovarian cancer cell lines and primary ovarian tumours
Figure 5. In vivo combination study of HXR9 and cisplatin. Antitu-
mor activity of HXR9 and cisplatin alone or in combination against
ovarian cancer (SKOV-3) xenografts. Nude female mice were inocu-
lated SC with 1 3 106 SKOV-3 cells (Day 0). Treatment was initi-
ated when tumours reached an approximate volume of 100 m3. An
initial dose of HXR9 was given IT at 100 mg/kg, followed by twice
weekly doses at 10 mg/kg. Cisplatin was administered IP at 3 mg/
kg weekly. Combinational studies consisted of both treatments;
PBS was used as a control. Arrows indicates drug administration.
A minimum of 6 mice in each group was set as the cut-off point
for each curve.
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demonstrates that these genes are profoundly dysregulated
compared to normal ovary. Increased expression of HOXA13,
B6, C13, D1 and D13 in EOC patients is associated with a
poor prognosis and a more aggressive malignancy. It is possi-
ble to target HOX function by disrupting its binding to PBX,
and further development of therapeutic compounds to
achieve this is warranted.
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